Novartis Fact Sheet, Novartis Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Novartis Fact Sheet    (NVRT)


Live Now: The Weekly Cash Summit, with Vijay Bhambwani

Here is the latest financial fact sheet of Novartis. For more details, see the Novartis quarterly results and Novartis share price and chart. For a sector overview, read our pharmaceuticals sector report.

NOVARTIS Price History

Price Rs 486.7
Mkt Cap Rs m 163,252
Vol '000 8.3
P/E X 715.1
P/CF X 297.1
EPS (TTM) Rs 0.7
% ch % 6.0
No. of shares m 335.46
% ch week % 8.5
% ch 1-mth % -13.3
% ch 12-mth % -29.8
52 week H/L Rs 780.0/420.1
(As on Mar 30, 2020 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NOVARTIS Financials

No. of Mths
Year Ending
12
Mar-15
12
Mar-16
12
Mar-17
12
Mar-18
12
Mar-19
5-Yr Chart
Click to enlarge
NOVARTIS EQUITY SHARE DATA
High Rs760982855758980 
Low Rs438556666579600 
Sales per share (Unadj.) Rs273.3215.8219.0228.4198.7 
Earnings per share (Unadj.) Rs24.862.019.131.721.0 
Diluted earnings per shareRs2.45.91.72.31.5 
Cash flow per share (Unadj.) Rs26.063.120.332.822.3 
Dividends per share (Unadj.) Rs10.0010.0010.0010.0010.00 
Adj. dividends per shareRs0.950.950.890.740.74 
Dividend yield (eoy) %1.71.31.31.51.3 
Book value per share (Unadj.) Rs313.5373.5307.0297.1307.5 
Adj. book value per shareRs29.935.627.421.922.6 
Shares outstanding (eoy) m31.9631.9629.9624.6924.69 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x2.23.63.52.94.0 
Avg P/E ratio x24.212.439.821.137.7 
P/CF ratio (eoy) x23.012.237.520.435.5 
Price / Book Value ratio x1.92.12.52.22.6 
Dividend payout %40.416.152.431.547.7 
Avg Mkt Cap Rs m19,14724,58022,77916,50519,508 
No. of employees `0001.20.80.70.70.6 
Total wages/salary Rs m2,0001,5671,3931,4451,171 
Avg. sales/employee Rs Th7,236.09,172.59,736.28,441.58,445.4 
Avg. wages/employee Rs Th1,657.22,083.22,066.82,163.62,015.7 
Avg. net profit/employee Rs Th655.42,636.8849.01,173.1891.0 
NOVARTIS INCOME DATA
Net Sales Rs m8,7346,8986,5625,6394,907 
Other income Rs m1,0768097021,718783 
Total revenues Rs m9,8107,7077,2647,3575,689 
Gross profit Rs m-39-113259-63123 
Depreciation Rs m4035362532 
Interest Rs m2275516 
Profit before tax Rs m9966599171,575858 
Minority Interest Rs m00000 
Prior Period Items Rs m16517000 
Extraordinary Inc (Exp) Rs m-631,696000 
Tax Rs m306389345792340 
Profit after tax Rs m7911,983572784518 
Gross profit margin %-0.4-1.63.9-1.12.5 
Effective tax rate %30.759.037.650.339.6 
Net profit margin %9.128.78.713.910.6 
NOVARTIS BALANCE SHEET DATA
Current assets Rs m10,63412,6379,7319,5228,055 
Current liabilities Rs m2,1072,0451,8303,2961,850 
Net working cap to sales %97.6153.6120.4110.4126.4 
Current ratio x5.06.25.32.94.4 
Inventory Days Days4238493745 
Debtors Days Days3527232834 
Net fixed assets Rs m85695746150 
Share capital Rs m160160141123123 
"Free" reserves Rs m9,85911,7769,0567,2137,469 
Net worth Rs m10,02011,9369,1967,3367,592 
Long term debt Rs m00000 
Total assets Rs m12,46114,32611,49911,1059,824 
Interest coverage x475.1314.7128.429.554.9 
Debt to equity ratio x00000 
Sales to assets ratio x0.70.50.60.50.5 
Return on assets %6.413.95.07.65.4 
Return on equity %7.916.66.210.76.8 
Return on capital %11.019.910.122.211.5 
Exports to sales %0.90.9000 
Imports to sales %14.221.8000 
Exports (fob) Rs m8060000 
Imports (cif) Rs m1,2441,503000 
Fx inflow Rs m1491861296158 
Fx outflow Rs m1,6451,8211,7343,6301,326 
Net fx Rs m-1,497-1,635-1,605-3,570-1,269 
NOVARTIS CASH FLOW
From Operations Rs m -596 566 -408 1,610 -1,943 
From Investments Rs m 7,189 -6,305 4,236 687 2,742 
From Financial Activity Rs m -377 -386 -3,318 -2,677 -298 
Net Cashflow Rs m 6,217 -6,125 510 -380 501 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 75.0%
Indian inst/Mut Fund 2.0%
FIIs 1.6%
ADR/GDR 0.0%
Free float 21.5%
Shareholders 41,647
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Sandoz House, Shivsagar Estate, Dr. Annie Besant Road, Mumbai-18
E-MAIL girish.tekchandani@novartis.com WEB www.novartis.in
TELEPHONE (022) 2495 8400 FAX (022) 2495 0221
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Sharepro Serv., 13 AB, Samhita Warehousing, Andheri (E), Mumbai-72
AUDITOR Lovelock and Lewes
CHM: C. Snook COMP SEC: Girish Tekchandani YEAR OF INC: 1947 BSE CODE: 500672 FV (Rs): 5 DIV YIELD (%): 0.2

More Pharmaceuticals Company Fact Sheets:   ELDER PHARMA  CIPLA  AJANTA PHARMA  GSK PHARMA  DISHMAN PHARMA  

Compare NOVARTIS With:   ELDER PHARMA  CIPLA  AJANTA PHARMA  GSK PHARMA  DISHMAN PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 1,375 Points; Nifty Ends Below 8,300 Mark(Closing)

Indian share markets witnessed selling pressure throughout the day and ended deep in the red with Sensex and Nifty witnessing a sharp fall during closing hours.

Views on news

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus (Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It. (Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World (The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon (Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NOVARTIS

NOVARTIS - TEVA PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS